title: Ariad suspends ponatinib sales.
abstract: Because of concerns about serious cardiovascular side effects, the U.S. Food and Drug Administration asked Ariad Pharmaceuticals to temporarily suspend sales and marketing of ponatinib to treat chronic myeloid leukemia in patients resistant to first-line therapy.
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D003132:Commerce; D004345:Drug Industry; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D011358:Product Surveillance, Postmarketing; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011724:Pyridazines / Q000009:adverse effects*; D056737:Safety-Based Drug Withdrawals; D013927:Thrombosis / Q000139:chemically induced; D014481:United States
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib